Ascendis Pharma
ASND
174 hedge funds and large institutions have $9.07B invested in Ascendis Pharma in 2020 Q4 according to their latest regulatory filings, with 34 funds opening new positions, 67 increasing their positions, 53 reducing their positions, and 11 closing their positions.
209% more first-time investments, than exits
New positions opened: 34 | Existing positions closed: 11
48% more capital inflows, than outflows
Capital inflows: $428M | Capital outflows: $290M
26% more repeat investments, than reductions
Existing positions increased: 67 | Existing positions reduced: 53
14% more funds holding
Funds holding: 152 → 174 (+22)
1.32% more ownership
Funds ownership: 94.25% → 95.57% (+1.3%)
8% less funds holding in top 10
Funds holding in top 10: 12 → 11 (-1)
20% less call options, than puts
Call options by funds: $29.7M | Put options by funds: $37.2M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Lone Pine Capital
Greenwich,
Connecticut
|
+$148M |
| 2 |
Spyglass Capital Management
San Francisco,
California
|
+$25.6M |
| 3 |
Artisan Partners
Milwaukee,
Wisconsin
|
+$25.2M |
| 4 |
Wellington Management Group
Boston,
Massachusetts
|
+$24.8M |
| 5 |
Victory Capital Management
San Antonio,
Texas
|
+$23.5M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
OrbiMed
New York
|
-$65.8M |
| 2 |
Farallon Capital Management
San Francisco,
California
|
-$41.3M |
| 3 |
Putnam Investments
Boston,
Massachusetts
|
-$29.7M |
| 4 |
Citadel Advisors
Miami,
Florida
|
-$29.5M |
| 5 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$26.2M |
ASND Hedge Fund Activity: Q4 2020 in Review
174 of the 5,679 institutional investors tracked by Wall St. Rank reported a position in Ascendis Pharma (ASND) for Q4 2020, worth a combined $9.07B — up 9.6% from $8.27B a quarter earlier.
Buyers outnumbered sellers: 34 funds opened new ASND positions and 11 closed out — a net gain of 23 holders — while 67 added to existing stakes and 53 trimmed.
The largest buyer was Lone Pine Capital, opening a new position worth an estimated $148M. The largest seller was OrbiMed, cutting an estimated $65.8M.
- 174 institutional investors held Ascendis Pharma (ASND) as of Q4 2020, up from 152 in Q3 2020.
- Funds reported $9.07B of Ascendis Pharma stock for Q4 2020, up 9.6% quarter-over-quarter.
- 34 funds opened new Ascendis Pharma positions in Q4 2020 and 11 closed out, a net change of +23 holders.
- The largest Ascendis Pharma buyer in Q4 2020 was Lone Pine Capital, an estimated $148M added.
- The largest Ascendis Pharma seller in Q4 2020 was OrbiMed, an estimated $65.8M sold.
Based on aggregated 13F filings for Q4 2020.